HC Wainwright Has Pessimistic View of MannKind Q3 Earnings

MannKind Corporation (NASDAQ:MNKD) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for MannKind in a note issued to investors on Thursday, August 6th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for MannKind’s Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at $0.00 EPS.

A number of other brokerages have also recently issued reports on MNKD. Wells Fargo & Company reduced their price objective on shares of MannKind from $14.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. Royal Bank Of Canada raised their price target on MannKind from $3.50 to $4.75 and gave the company a “sector perform” rating in a report on Thursday, May 7th. Mizuho cut their target price on MannKind from $8.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen cut shares of MannKind from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.22.

MannKind Stock Down 3.1%

NASDAQ MNKD opened at $3.73 on Friday. The stock’s 50-day moving average price is $3.97 and its 200-day moving average price is $3.71. The company has a market capitalization of $1.20 billion, a P/E ratio of -28.69 and a beta of 1.12. MannKind has a 52 week low of $2.23 and a 52 week high of $6.51.

Institutional Trading of MannKind

Institutional investors have recently modified their holdings of the stock. Krilogy Financial LLC acquired a new stake in shares of MannKind during the 1st quarter worth approximately $28,000. Independent Financial Group LLC acquired a new position in MannKind in the first quarter valued at $31,000. Caitong International Asset Management Co. Ltd raised its position in MannKind by 108.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,927 shares during the last quarter. Waverly Advisors LLC acquired a new position in shares of MannKind in the first quarter valued at approximately $43,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of MannKind in the 4th quarter worth $45,000. Institutional investors and hedge funds own 49.55% of the company’s stock.

Insider Activity at MannKind

In other news, Director Steven B. Binder sold 39,051 shares of MannKind stock in a transaction on Friday, August 7th. The stock was sold at an average price of $4.06, for a total transaction of $158,547.06. Following the completion of the sale, the director directly owned 785,867 shares in the company, valued at approximately $3,190,620.02. This trade represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.60% of the company’s stock.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: A Seeking Alpha analysis argued that two new FDA approvals could significantly accelerate growth for two of MannKind’s established products. The company also benefits from three revenue streams, while its existing liquidity may fund operations and product launches for roughly 2.3 years. MannKind: New Approvals Majorly Increase MannKind’s Prospects
• Neutral Sentiment: HC Wainwright continues to rate MannKind Buy, suggesting the analyst sees longer-term upside despite near-term earnings revisions. The firm forecasts a path toward profitability, with projected EPS of $0.27 in 2029 and $0.68 in 2030, though both estimates were reduced. MannKind analyst estimates
• Negative Sentiment: HC Wainwright lowered its EPS forecast for the third quarter of 2026 to a loss of $0.10 from a loss of $0.05, and reduced its fourth-quarter estimate to a loss of $0.06 from $0.05. These changes point to weaker near-term profitability than previously expected. MannKind quarterly earnings estimates
• Negative Sentiment: The analyst also cut full-year 2026 EPS expectations to a loss of $0.27 from a loss of $0.18, and reduced the 2027 forecast to a loss of $0.06 from projected earnings of $0.04. The 2028 estimate was lowered to breakeven from $0.12 per share. MannKind annual earnings estimates
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was cut to $0.27 from $0.39, and 2030 EPS to $0.68 from $0.82. Although profitability remains part of the outlook, the revisions imply more cautious expectations for MannKind’s future earnings growth. MannKind long-term earnings estimates

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).